# OrthoPediatrics Corp. (KIDS)

> Source: Nexqual · https://nexqual.com/KIDS · data as of 2026-10-28 20:00 UTC · cite as "Nexqual, OrthoPediatrics Corp. (KIDS), nexqual.com/KIDS" · informational, not investment advice.

**Price:** USD 30.8 (+29.30% on the day) · last close of Oct 28, 2026; US market after hours, not a live price. Prev close 23.82 · day 24.79–31.51 · 52w 14.42–31.51 · market cap $804M · NGM

## Key facts
- Last four reported quarters (through Sep 30, 2026): revenue $264M, net income -$33.9M (-12.8% margin), free cash flow $3.2M (SEC filings).
- Insider open-market sales, last ~7 months: 12 Form 4 filings, $46.7M; 12 not under a Rule 10b5-1 plan ($46.7M); 0 by opportunistic insiders, 0 by routine insiders (three-year test, Cohen, Malloy & Pomorski 2012).
- Analysts: Buy (mean 1.86 on a 1–5 scale) (7 analysts), mean target USD 30.25 (range 27–35).
- Total return with dividends: 1Y +87.1% vs S&P 500 +13.6%; 5Y -56.7% vs S&P 500 +79.8%.
- Next earnings: 2026-10-27, EPS estimate USD -0.19, revenue estimate $69.1M.

## Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $98.0M | $122M | $149M | $205M | $236M | $264M |
| Gross profit | $73.4M | $90.7M | $111M | $149M | $173M | — |
| Operating income | -$18.0M | -$25.4M | -$26.8M | -$35.0M | -$39.2M | -$24.8M |
| Net income | -$16.3M | $1.3M | -$21.0M | -$37.8M | -$39.6M | -$33.9M |
| EPS (diluted) | -$0.84 | $0.06 | -$0.92 | -$1.64 | -$1.69 | — |
| Free cash flow | -$21.2M | -$31.8M | -$43.9M | -$41.3M | -$16.0M | $3.2M |
| Gross margin | 74.9% | 74.1% | 74.8% | 72.6% | 73.1% | — |
| Operating margin | -18.4% | -20.8% | -18.0% | -17.1% | -16.6% | -9.4% |
| Net margin | -16.6% | 1.0% | -14.1% | -18.5% | -16.8% | -12.8% |
| Revenue growth | +37.9% | +24.7% | +21.6% | +37.6% | +15.4% | — |
| Cash + short-term investments | $53.5M | $118M | $80.3M | $68.8M | $60.9M | — |
| Total debt | $1.0M | $907K | $11.1M | $77.5M | $106M | — |
Fiscal years end Dec. EPS is split-adjusted.

## Valuation (price ÷ last four quarters, through Sep 30, 2026)
P/S 3.0x · EV/Sales 3.3x · P/FCF 252.9x · P/B 2.4x · FCF yield 0.40% · Earnings yield -4.21% · Net debt $60.4M · EV $865M

## Insider sales (SEC Form 4, open-market, last ~7 months)
0 of 12 under a Rule 10b5-1 trading plan (scheduled in advance). Unplanned sales were timed by the insider.
| Trade date | Insider | Role | Shares | Value | % of holdings sold | 10b5-1 plan | Insider type |
|---|---|---|---|---|---|---|---|
| 2026-09-10 | Squadron Capital Llc |  | 302,369 | $6.4M | 4.6% | No | Too little history (no open-market trades in 2023–2025) |
| 2026-09-10 | Pritzker Jennifer N. |  | 302,369 | $6.4M | 4.6% | No | Too little history (no open-market trades in 2023–2025) |
| 2026-09-10 | Pelizzon David R | Director | 302,369 | $6.4M | 4.6% | No | Too little history (no open-market trades in 2023–2025) |
| 2026-09-02 | Squadron Capital Llc |  | 22,500 | $525K | 0.3% | No | Too little history (no open-market trades in 2023–2025) |
| 2026-09-02 | Pritzker Jennifer N. |  | 22,500 | $525K | 0.3% | No | Too little history (no open-market trades in 2023–2025) |
| 2026-09-02 | Pelizzon David R | Director | 22,500 | $525K | 0.3% | No | Too little history (no open-market trades in 2023–2025) |
| 2026-08-28…2026-09-01 | Squadron Capital Llc |  | 336,831 | $7.8M | 4.9% | No | Too little history (no open-market trades in 2023–2025) |
| 2026-08-28…2026-09-01 | Pritzker Jennifer N. |  | 336,831 | $7.8M | 4.9% | No | Too little history (no open-market trades in 2023–2025) |
| 2026-08-28…2026-09-01 | Pelizzon David R | Director | 336,831 | $7.8M | 4.9% | No | Too little history (no open-market trades in 2023–2025) |
| 2026-08-24…2026-08-26 | Pritzker Jennifer N. |  | 38,300 | $943K | 0.6% | No | Too little history (no open-market trades in 2023–2025) |
| 2026-08-24…2026-08-26 | Squadron Capital Llc |  | 38,300 | $943K | 0.6% | No | Too little history (no open-market trades in 2023–2025) |
| 2026-08-24…2026-08-26 | Pelizzon David R | Director | 38,300 | $943K | 0.6% | No | Too little history (no open-market trades in 2023–2025) |
% of holdings sold = shares sold ÷ (shares sold + all holdings the insider reported on that Form 4, direct and through trusts).
Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.

## Analysts
Consensus Buy (mean 1.86 on a 1–5 scale), 7 analysts; mean target USD 30.25 (low 27, high 35).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-28 | Lake Street | Target raised | Buy | $34 → $38 |
| 2026-10-28 | Canaccord Genuity | Target raised | Buy | $28 → $30 |
| 2026-10-28 | Truist Securities | Target raised | Hold | $22 → $28 |
| 2026-10-28 | TD Cowen | Target raised | Buy | $23 → $28 |
| 2026-10-28 | Stifel | Target raised | Buy | $24 → $27 |
| 2026-10-28 | Piper Sandler | Target raised | Overweight | $25 → $30 |
| 2026-10-28 | BTIG | Target raised | Buy | $29 → $30 |
| 2026-09-14 | BTIG | Reiterated | Buy | $29 |
| 2026-08-20 | BTIG | Target raised | Buy | $24 → $29 |
| 2026-08-05 | Piper Sandler | Target raised | Overweight | $22 → $25 |
| 2026-08-05 | Needham | Target raised | Buy | $30 → $35 |
| 2026-07-16 | Truist Securities | Target raised | Hold | $17 → $20 |

## Total return (dividends reinvested)
|  | 1Y (from 2025-10-29) | 5Y (from 2021-10-25) |
|---|---|---|
| Total return | +87.1% | -56.7% |
| S&P 500 (SPY) | +13.6% | +79.8% |
| Per year | +87.5% | -15.4% |
| Volatility (annualized) | 49.1% | 46.5% |
| Max drawdown | -27.2% (Jan 2026→Apr 2026) | -78.7% (Nov 2021→Mar 2026) |

## Peers (Medical Devices)
ATEC (Alphatec Holdings, Inc.) USD 11.45 +5.34% · INSP (Inspire Medical Systems, Inc.) USD 70.97 -0.46% · ESTA (Establishment Labs Holdings Inc) USD 68.97 +3.02% · BFLY (Butterfly Network, Inc.) USD 7.81 +5.83% · UFPT (UFP Technologies, Inc.) USD 286 -3.00% · TMDX (TransMedics Group, Inc.) USD 66.9 -4.06%

## More
Full page: https://nexqual.com/KIDS · Free keyless MCP server with the same data and citations: https://mcp.nexqual.com/mcp · Guide for agents: https://nexqual.com/agents · https://nexqual.com/llms.txt

## Supply chain and relationships (SEC annual reports)

Named in KIDS's own 10-K filed 2026-03-04 (https://www.sec.gov/Archives/edgar/data/1425450/000142545026000013/kids-20251231.htm):

| Relationship | Company | Sentence in the filing |
|---|---|---|
| Supplier | Structure Medical | "In addition, we currently use Structure Medical, LLC, a Squadron-affiliated entity, as a supplier for some of the components of our products." |
| Competitor | Johnson & Johnson (JNJ) | "We have competitors in each of our three product categories, including Johnson & Johnson MedTech (a subsidiary of Johnson & Johnson), Medtronic plc, Smith & Nephew plc, Orthofix, and Hanger clinics." |

## Revenue by product line (quarter ended 2026-09-30)

| Line | Revenue | Share | YoY |
|---|---|---|---|
| Trauma and deformity | $52.6M | 72.4% | +19.2% |
| Scoliosis | $19.2M | 26.4% | +17.9% |
| Sports medicine/other | $866,000 | 1.2% | +2.4% |
| Total revenue | $72.7M | 100% | — |

## Revenue by region (quarter ended 2026-09-30)

| Line | Revenue | Share | YoY |
|---|---|---|---|
| U.S. | $57.9M | 79.7% | +18.8% |
| International | $14.8M | 20.3% | +17.9% |
| Total revenue | $72.7M | 100% | — |

## Analyst estimates and revisions

| Period | EPS est. | 90d ago | Change | Revenue est. | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends 2026-12-31) | $-0.19 | $-0.18 | −$0.01 | $69.1M | 5 |
| Next quarter (ends 2027-03-31) | $-0.34 | $-0.28 | −$0.07 | $66.9M | 4 |
| Current fiscal year (ends 2026-12-31) | $-1.09 | $-1.05 | −$0.04 | $271.6M | 4 |
| Next fiscal year (ends 2027-12-31) | $-0.85 | $-0.68 | −$0.17 | $304.5M | 4 |

## Options: expected move (Cboe, 15-min delayed)

| Expiration | Days | ATM IV | Expected move |
|---|---|---|---|
| 2026-11-20 | 23 | 43.9% | ±8.8% |
| 2026-12-18 | 51 | 48.0% | ±14.2% |
| 2027-01-15 | 79 | 57.8% | ±21.2% |
| 2027-04-16 | 170 | 37.5% | ±20.0% |

## Earnings history and stock reaction
| Results filed | Quarter | EPS | Consensus | Surprise | Stock reaction |
|---|---|---|---|---|---|
| Oct 27, 2026 | Quarter ended Sep 30, 2026 | −$0.23 | −$0.21 | Miss −9.5% | +28.2% |
| Aug 4, 2026 | Quarter ended Jun 30, 2026 | −$0.26 | −$0.28 | Beat +7.1% | +6.9% |
| Apr 30, 2026 | Quarter ended Mar 31, 2026 | −$0.42 | −$0.44 | Beat +4.5% | +6.8% |
| Feb 26, 2026 | Quarter ended Dec 31, 2025 | −$0.26 | −$0.29 | Beat +10.3% | +14.7% |
| Jan 12, 2026 | Quarter ended Dec 31, 2025 | −$0.26 | −$0.29 | Beat +10.3% | +2.1% |
| Oct 28, 2025 | — | — | — | — | -2.9% |
| Oct 9, 2025 | — | — | — | — | -9.9% |
| Aug 5, 2025 | — | — | — | — | -12.8% |
EPS as reported against the analyst consensus before the release; surprise uses the cent-rounded figures shown (in dollars when EPS and consensus have opposite signs). Stock reaction = close before the results to close after (the first close following a release after the bell or before the open).

## Recent SEC filings (last 120 days)
| Filed | Form | What it says | Filing |
|---|---|---|---|
| 2026-10-28 | 10-Q | Quarterly report · period ended Sep 30, 2026 | https://www.sec.gov/Archives/edgar/data/1425450/000142545026000094/0001425450-26-000094-index.htm |
| 2026-10-27 | 8-K | Regulation FD disclosure | https://www.sec.gov/Archives/edgar/data/1425450/000142545026000092/0001425450-26-000092-index.htm |
| 2026-10-27 | 8-K | Quarterly results | https://www.sec.gov/Archives/edgar/data/1425450/000142545026000091/0001425450-26-000091-index.htm |
| 2026-09-11 | Schedule 13D/A | Squadron Capital LLC, Squadron Capital Holdings LLC: 23.9% of shares, 5%+ holder that may seek to influence the company (amended) | https://www.sec.gov/Archives/edgar/data/1425450/000119312526388676/0001193125-26-388676-index.htm |
| 2026-09-01 | Schedule 13D/A | Squadron Capital LLC, Squadron Capital Holdings LLC: 25.2% of shares, 5%+ holder that may seek to influence the company (amended) | https://www.sec.gov/Archives/edgar/data/1425450/000119312526378878/0001193125-26-378878-index.htm |
| 2026-08-05 | 10-Q | Quarterly report · period ended Jun 30, 2026 | https://www.sec.gov/Archives/edgar/data/1425450/000142545026000070/0001425450-26-000070-index.htm |
| 2026-08-04 | 8-K | Regulation FD disclosure | https://www.sec.gov/Archives/edgar/data/1425450/000142545026000067/0001425450-26-000067-index.htm |
| 2026-08-04 | 8-K | Quarterly results | https://www.sec.gov/Archives/edgar/data/1425450/000142545026000066/0001425450-26-000066-index.htm |
| 2026-07-15 | Schedule 13G/A | Integrated Core Strategies (US) LLC, Millennium Management LLC: 3.2% of shares, passive 5%+ holder (amended) | https://www.sec.gov/Archives/edgar/data/1425450/000110465926083981/0001104659-26-083981-index.htm |
Source: SEC EDGAR. Quotes are the opening words of each item as filed.